161 related articles for article (PubMed ID: 24668609)
1. Preclinical evaluation of the combination of mTOR and proteasome inhibitors with radiotherapy in malignant peripheral nerve sheath tumors.
Yamashita AS; Baia GS; Ho JS; Velarde E; Wong J; Gallia GL; Belzberg AJ; Kimura ET; Riggins GJ
J Neurooncol; 2014 May; 118(1):83-92. PubMed ID: 24668609
[TBL] [Abstract][Full Text] [Related]
2. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
3. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
5. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
[TBL] [Abstract][Full Text] [Related]
6. Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
Watson AL; Anderson LK; Greeley AD; Keng VW; Rahrmann EP; Halfond AL; Powell NM; Collins MH; Rizvi T; Moertel CL; Ratner N; Largaespada DA
Oncotarget; 2014 Mar; 5(6):1502-14. PubMed ID: 24681606
[TBL] [Abstract][Full Text] [Related]
7. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
Ghadimi MP; Lopez G; Torres KE; Belousov R; Young ED; Liu J; Brewer KJ; Hoffman A; Lusby K; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2012 Aug; 11(8):1758-69. PubMed ID: 22848094
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
9. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
10. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
Johansson G; Mahller YY; Collins MH; Kim MO; Nobukuni T; Perentesis J; Cripe TP; Lane HA; Kozma SC; Thomas G; Ratner N
Mol Cancer Ther; 2008 May; 7(5):1237-45. PubMed ID: 18483311
[TBL] [Abstract][Full Text] [Related]
11. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
12. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
13. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Kivlin CM; Watson KL; Al Sannaa GA; Belousov R; Ingram DR; Huang KL; May CD; Bolshakov S; Landers SM; Kalam AA; Slopis JM; McCutcheon IE; Pollock RE; Lev D; Lazar AJ; Torres KE
Cancer Biol Ther; 2016; 17(2):129-38. PubMed ID: 26650448
[TBL] [Abstract][Full Text] [Related]
14. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
Banerjee S; Byrd JN; Gianino SM; Harpstrite SE; Rodriguez FJ; Tuskan RG; Reilly KM; Piwnica-Worms DR; Gutmann DH
Cancer Res; 2010 Feb; 70(4):1356-66. PubMed ID: 20124472
[TBL] [Abstract][Full Text] [Related]
15. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
Li J; Liu Z; Li Y; Jing Q; Wang H; Liu H; Chen J; Feng J; Shao Q; Fu R
J Investig Med; 2019 Jan; 67(1):39-47. PubMed ID: 29997148
[TBL] [Abstract][Full Text] [Related]
16. Impaired Pten expression in human malignant peripheral nerve sheath tumours.
Bradtmöller M; Hartmann C; Zietsch J; Jäschke S; Mautner VF; Kurtz A; Park SJ; Baier M; Harder A; Reuss D; von Deimling A; Heppner FL; Holtkamp N
PLoS One; 2012; 7(11):e47595. PubMed ID: 23139750
[TBL] [Abstract][Full Text] [Related]
17. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
18. MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro.
Fischer-Huchzermeyer S; Dombrowski A; Wilke G; Stahn V; Streubel A; Mautner VF; Harder A
PLoS One; 2017; 12(11):e0187700. PubMed ID: 29131833
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
[TBL] [Abstract][Full Text] [Related]
20. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
